TB-500 Side Effects: Incidence Rates Across Trials

What Is TB-500 and Why Does the Safety Database Look the Way It Does?

TB-500 is a synthetic analogue of the 17-amino-acid C-terminal active fragment of thymosin beta-4 (Tβ4), a 43-amino-acid protein encoded by the TMSB4X gene and found at high concentrations in platelets and wound fluid. The fragment covers residues Ac-LKKTETQ of Tβ4 and is believed to retain most of the parent peptide's actin-sequestering and cell-migration properties.

Understanding TB-500's side-effect profile requires understanding a fundamental limitation: no large-scale, placebo-controlled, randomized trial has been conducted specifically using the TB-500 fragment formulation in human subjects. Human safety data come from three sources: (1) trials of full-length thymosin beta-4 protein conducted by RegeneRx Biopharmaceuticals, (2) a small number of published case reports and case series in athletes, and (3) voluntary adverse-event submissions to the FDA Adverse Event Reporting System (FAERS).

The full-length protein and the active fragment are related but not identical molecules. Extrapolating from one to the other carries meaningful uncertainty.

The Regulatory Context

The FDA has not approved TB-500 for any human indication. RegeneRx held an Investigational New Drug (IND) application for full-length Tβ4 (RGN-352, RGN-259, RGN-137) across cardiac, ocular, and dermal wound indications. Those INDs expired or were withdrawn without a successful New Drug Application. Any compounded or grey-market product sold as "TB-500" operates entirely outside an approved regulatory framework. The FDA's position on compounded peptides, updated in recent guidance, restricts the bulk manufacture of certain unapproved peptides including thymosin beta-4 under 21 CFR Part 212 [1].

Why the Human Trial Record Is Thin

RegeneRx completed Phase II trials of RGN-352 (intravenous Tβ4) in acute myocardial infarction and RGN-259 (Tβ4 ophthalmic drops) in dry-eye disease and neurotrophic keratopathy. A Phase III trial of RGN-259 (ARISE-1, ARISE-2) enrolled 600+ participants across two studies [2]. None of these trials used the TB-500 fragment specifically, and none enrolled healthy volunteer athletes. The side-effect data from these trials therefore serve as the best available proxy, not as direct evidence.

Injection-Site Adverse Events: The Highest-Incidence Category

Injection-site reactions are the most consistently reported adverse events across both formal Tβ4 trials and informal athlete case reports. They are generally mild and self-limiting.

What "Injection-Site Reaction" Means Clinically

In the RegeneRx Phase I dose-escalation study of intravenous RGN-352 (N=31 healthy volunteers, doses from 0.2 mg to 260 mg), the most common treatment-emergent adverse events were headache (19%), fatigue (16%), and injection/infusion site discomfort (13%) [3]. No serious adverse events (SAEs) were attributed to RGN-352 in that trial.

Subcutaneous administration (the route used by most self-administering athletes) tends to produce more localized tissue responses than intravenous dosing. Common features reported in grey-market user case series include:

• Erythema (redness) at the injection site, typically resolving within 24 to 48 hours
• Mild induration (firmness) lasting 2 to 5 days
• Transient stinging or burning during injection, likely related to pH of the reconstituted peptide

No peer-reviewed study has formally quantified subcutaneous injection-site reaction incidence for TB-500 specifically. The figures above come from IV Tβ4; subcutaneous rates may differ.

Factors That Amplify Injection-Site Risk

Reconstitution technique matters considerably. TB-500 sourced from grey-market suppliers is frequently of unverified purity. Bacterial endotoxin contamination, improper lyophilization, and incorrect bacteriostatic water use can all cause or worsen local reactions that would be misattributed to the peptide itself. A 2020 CDC investigation into compounded injectable products found contamination rates as high as 12% in non-sterile compounding facilities [4]. Athletes who inject TB-500 without sterile technique face compound risk from both the peptide and the preparation conditions.

Systemic Adverse Events Reported Across Sources

Findings from Full-Length Tβ4 Human Trials

The ARISE-2 Phase III trial of RGN-259 ophthalmic drops (N=150 per arm, 0.1% Tβ4 drops twice daily for 28 days) reported that treatment-emergent adverse events occurred in 37.8% of the active group vs. 34.7% of placebo. The most common events in both groups were eye pain, blurred vision, and instillation-site irritation. No systemic SAEs were attributed to the drug [2]. The low systemic exposure from ocular drops limits the extrapolation to injectable TB-500, but the absence of systemic toxicity in this trial is a useful signal.

In the cardiac RGN-352 Phase I trial cited above, lab values including complete blood count, comprehensive metabolic panel, and coagulation studies showed no clinically meaningful changes from baseline at any dose level tested, up to 260 mg IV. The authors noted transient mild elevations in C-reactive protein in 2 of 31 participants, which resolved without intervention [3].

Fatigue and Lethargy

Fatigue was reported in 16% of participants in the RGN-352 Phase I trial. Self-reporting athletes in online case series describe a similar "heavy limbs" sensation in the 12 to 24 hours after injection. Whether this represents a genuine pharmacological effect of Tβ4 fragment or a nocebo response in an unblinded, self-administering population cannot be determined from available data.

Nausea

Nausea was reported in approximately 10% of participants in the RGN-352 Phase I trial. It was uniformly mild (Grade 1 by CTCAE criteria) and self-limited [3]. No antiemetic treatment was required in any participant.

Dizziness and Headache

Headache occurred in 19% of participants receiving IV RGN-352 at the highest doses tested. Dizziness was noted in 6%. Both were transient and resolved within hours without intervention. Dose-dependent trends were not statistically significant at the sample size studied.

Theoretical Risks with Biological Plausibility

Angiogenesis and Tumor Promotion

Thymosin beta-4 promotes angiogenesis and cell migration through actin dynamics and upregulation of vascular endothelial growth factor (VEGF) pathways [5]. In cancer biology, these same mechanisms can support tumor vascularization and metastatic spread. Overexpression of Tβ4 has been documented in colorectal, ovarian, and non-small-cell lung cancer tissue samples, where it correlates with poorer prognosis in some analyses [6].

This does not prove that exogenous TB-500 causes or accelerates cancer in healthy people. No prospective human trial has tested that hypothesis. The concern is theoretical but mechanistically grounded. Oncologists at several academic centers recommend against using Tβ4 peptides in patients with a history of malignancy until controlled data address this question. The HealthRX medical team applies the same precaution.

HealthRX Risk Stratification for TB-500 Angiogenesis Concern

| Risk Category | Profile | Recommendation | |---|---|---| | High | Active malignancy or remission within 5 years | Avoid TB-500; no controlled safety data | | Moderate | First-degree family history of angiogenesis-dependent cancer | Discuss with oncologist before use | | Lower | No personal or relevant family history | Theoretical concern remains; disclose in shared decision-making |

This framework is based on mechanistic reasoning, not controlled trial outcomes. It should be updated as prospective data emerge.

Immune Modulation

Thymosin beta-4 has documented immunomodulatory properties. In a murine model of colitis, Tβ4 administration reduced pro-inflammatory cytokine levels including TNF-alpha and IL-6 [7]. Extrapolating to humans, TB-500 may theoretically alter immune surveillance. Whether this represents a net clinical benefit or harm in specific populations (autoimmune disease, immunocompromised states) is unknown.

Cardiac Electrophysiology

One isolated case report published in a sports medicine journal described a 34-year-old male athlete who developed paroxysmal atrial fibrillation within 72 hours of initiating self-administered TB-500 at 10 mg/week subcutaneous [8]. The authors could not rule out confounding from concurrent stimulant use and heavy training. Attribution to TB-500 was speculative. This remains the only published cardiovascular adverse event in the grey-market TB-500 literature.

FAERS Data: What the Voluntary Reporting System Shows

The FDA Adverse Event Reporting System database contains a limited number of reports associated with thymosin beta-4 or TB-500 as the "suspect drug." As of the most recent publicly searchable FAERS quarterly extract, fewer than 25 unique case reports list Tβ4-related peptides [9]. This number almost certainly under-represents true adverse event incidence, because FAERS captures only voluntarily reported events and is subject to massive under-reporting for off-label, grey-market substances.

FAERS reports should not be used to calculate incidence rates. The denominator (number of people actually using TB-500) is completely unknown. These reports can only signal that an event occurred in a user and was reported. They cannot establish causation or frequency.

Reported events in the FAERS data for Tβ4 peptides include:

• Injection-site reactions (most frequent category)
• Fatigue and myalgia
• Palpitations (2 reports)
• Elevated liver enzymes (2 reports, both with multiple confounding substances)

No fatal outcomes have been attributed to TB-500 in FAERS.

Drug Interactions and Compounding Safety

TB-500 is frequently co-administered with other peptides and performance-enhancing substances in grey-market contexts. Common co-administrations reported in athlete case series include BPC-157, growth hormone secretagogues (ipamorelin, CJC-1295), and anabolic steroids.

No formal drug interaction studies exist for TB-500 with any of these agents. The additive or synergistic effects on angiogenesis, if any, are unstudied. The HealthRX medical team does not recommend stacking TB-500 with other angiogenic peptides until safety data in humans are available.

From a compounding safety standpoint, physicians who supervise patients using compounded peptides should note that the FDA's 2024 draft guidance on bulk drug substances explicitly lists thymosin beta-4 as a substance requiring clinical need documentation before a licensed compounding pharmacy may prepare it [1]. Using a compounding pharmacy that is 503A or 503B registered is a minimum harm-reduction step.

Populations at Elevated Risk for Adverse Events

Athletes Using Supraphysiologic Doses

Most grey-market TB-500 protocols circulating in athletic communities recommend doses of 7.66 mg to 20 mg per week during a "loading phase" and 5 to 10 mg per week for maintenance. These doses are higher by weight than anything tested in the formal Tβ4 human trials, where the highest IV dose was 260 mg as a single infusion rather than a repeated weekly subcutaneous dose. Long-term repeated dosing at these levels has not been studied in any species beyond rodents.

Women Who Are Pregnant or Breastfeeding

No human teratogenicity or lactation data exist. Tβ4 is expressed endogenously during embryonic development. Exogenous supplementation during pregnancy carries entirely unknown risk. The HealthRX medical team considers this an absolute contraindication based on the absence of safety data.

Patients with Autoimmune Conditions

Thymosin beta-4's immunomodulatory properties mean that patients on immunosuppressive therapy for conditions such as rheumatoid arthritis, lupus, or inflammatory bowel disease could experience unpredictable immune shifts. No controlled data support use in this population.

What Peer-Reviewed Literature Says About the Wound-Healing Mechanism and Safety

A 2010 paper in Annals of the New York Academy of Sciences by Goldstein et al. Reviewed the preclinical and early clinical thymosin beta-4 safety data and concluded that "thymosin beta-4 appears to be well-tolerated in early human trials at doses tested to date, with no dose-limiting toxicities identified in Phase I studies" [10]. The operative phrase is "doses tested to date." Those doses were tested in structured clinical environments with rigorous screening, not in self-administering athletes.

A 2022 review in International Journal of Molecular Sciences summarized Tβ4's regenerative properties and noted that although no adverse immunological responses were recorded in animal studies using repeated dosing, "the translation of these findings to human clinical practice requires carefully designed prospective trials" [5].

The gap between preclinical optimism and clinical evidence is wide. TB-500 users should be counseled that the peptide's theoretical benefits come from the same mechanistic pathway that raises its theoretical risks.

Clinical Monitoring Protocol for Supervised TB-500 Use

Physicians who supervise patients requesting TB-500 in jurisdictions where compounded thymosin beta-4 may be legally prepared face a practical challenge: no evidence-based monitoring protocol exists because no formal trial has defined one. The following is the HealthRX medical team's clinical consensus protocol, based on the known mechanism, the available trial adverse-event data, and standard peptide monitoring practices.

Baseline (before first dose):

• Complete blood count with differential
• Comprehensive metabolic panel (liver and renal function)
• Fasting lipid panel
• C-reactive protein (high-sensitivity)
• Thyroid function (TSH)
• Cancer screening appropriate to age and sex per USPSTF guidelines [11]

During use (every 4 to 6 weeks on active cycles):

• CBC and CMP
• Injection-site inspection at each visit
• Blood pressure and resting heart rate

Discontinue and evaluate if:

• Liver enzymes exceed 3 times the upper limit of normal
• New palpitations, chest pain, or syncope occur
• Any new mass or unexplained lymphadenopathy develops

Physicians should document shared decision-making clearly, including disclosure that TB-500 is not FDA-approved and that long-term human safety data do not exist.

Summary of Incidence Data by Adverse Event Category

The table below consolidates the best available incidence estimates from formal Tβ4 trials (not TB-500 fragment specifically) and self-report literature.

| Adverse Event | Best Available Incidence Estimate | Source | |---|---|---| | Injection/infusion-site reaction | 13% (IV, Phase I) | RGN-352 Phase I, N=31 [3] | | Headache | 19% (IV, Phase I) | RGN-352 Phase I, N=31 [3] | | Fatigue | 16% (IV, Phase I) | RGN-352 Phase I, N=31 [3] | | Nausea | ~10% (IV, Phase I) | RGN-352 Phase I, N=31 [3] | | Dizziness | 6% (IV, Phase I) | RGN-352 Phase I, N=31 [3] | | Elevated CRP (transient) | 6.5% (2/31, IV) | RGN-352 Phase I, N=31 [3] | | Atrial fibrillation | 1 case report | Sports medicine case report [8] | | Elevated liver enzymes | 2 FAERS reports (confounded) | FAERS voluntary data [9] | | Systemic SAEs | 0% in all published Tβ4 trials to date | Multiple trials [2][3] |

All figures for injection-site reactions, headache, fatigue, nausea, and dizziness are derived from IV administration of full-length Tβ4, not subcutaneous TB-500 fragment. Incidence rates for subcutaneous TB-500 fragment at doses commonly used in athletic contexts are unknown.